Syndax Pharmaceuticals Inc — All Filings
629 total filings on record
Public companies registered with the SEC are required to file periodic reports, disclosures, and notices throughout the year. The most important are the 10-K (annual report), 10-Q (quarterly report), and 8-K (material event notice). Use the filters below to narrow by form type.
All
10-K
10-K/A
10-Q
144
3
4
4/A
424B4
424B5
8-A12B
8-K
8-K/A
ARS
CERTNAS
CORRESP
CT ORDER
D
DEF 14A
DEFA14A
DRS
DRS/A
DRSLTR
EFFECT
PRE 14A
REGDEX
RW
S-1
S-1/A
S-3
S-3ASR
S-8
SC 13D
SC 13D/A
SC 13G
SC 13G/A
SCHEDULE 13G
SCHEDULE 13G/A
UPLOAD
| Form | Description | Accession Number | Filed | Period |
|---|---|---|---|---|
| SCHEDULE 13G/A | — | 0001576419-25-000656 | Apr 17, 2025 | — |
| DEF 14A | DEF 14A | 0000950170-25-048472 | Apr 1, 2025 | — |
| DEFA14A | DEFA14A | 0000950170-25-048476 | Apr 1, 2025 | — |
| ARS | ARS | 0000950170-25-048489 | Apr 1, 2025 | Dec 31, 2024 |
| 4 | 4 | 0000950170-25-039787 | Mar 17, 2025 | Mar 14, 2025 |
| SCHEDULE 13G/A | — | 0000902219-25-000138 | Mar 7, 2025 | — |
| 4 | 4 | 0000950170-25-034634 | Mar 6, 2025 | Mar 4, 2025 |
| 144 | — | 0001950047-25-001520 | Mar 4, 2025 | — |
| S-8 | S-8 | 0000950170-25-031354 | Mar 4, 2025 | — |
| 8-K | 8-K | 0000950170-25-030392 | Mar 3, 2025 | — |
| 10-K | 10-K | 0000950170-25-030394 | Mar 3, 2025 | Dec 31, 2024 |
| SCHEDULE 13G/A | — | 0001085146-25-001726 | Feb 14, 2025 | — |
| 4 | 4 | 0000950170-25-019000 | Feb 12, 2025 | Feb 10, 2025 |
| 4 | 4 | 0000950170-25-019005 | Feb 12, 2025 | Feb 10, 2025 |
| 4 | 4 | 0000950170-25-018993 | Feb 12, 2025 | Feb 10, 2025 |
| 144 | — | 0001959173-25-000833 | Feb 10, 2025 | — |
| 144 | — | 0001959173-25-000835 | Feb 10, 2025 | — |
| 144 | — | 0001959173-25-000841 | Feb 10, 2025 | — |
| 4 | 4 | 0000950170-25-016374 | Feb 7, 2025 | Feb 5, 2025 |
| 4 | 4 | 0000950170-25-016346 | Feb 7, 2025 | Feb 5, 2025 |
| 4 | 4 | 0000950170-25-016384 | Feb 7, 2025 | Feb 5, 2025 |
| 4 | 4 | 0000950170-25-016357 | Feb 7, 2025 | Feb 5, 2025 |
| 4 | 4 | 0000950170-25-016363 | Feb 7, 2025 | Feb 5, 2025 |
| 4 | 4 | 0000950170-25-016369 | Feb 7, 2025 | Feb 5, 2025 |
| 4 | 4 | 0000950170-25-016389 | Feb 7, 2025 | Feb 5, 2025 |
| 4 | 4 | 0000950170-25-016380 | Feb 7, 2025 | Feb 5, 2025 |
| 4 | 4 | 0000950170-25-016391 | Feb 7, 2025 | Feb 5, 2025 |
| 4 | 4 | 0000950170-25-016351 | Feb 7, 2025 | Feb 5, 2025 |
| SCHEDULE 13G | — | 0000902664-25-000388 | Jan 22, 2025 | — |
| 8-K | 8-K | 0000950170-24-139121 | Dec 20, 2024 | — |
| SC 13G/A | — | 0002012383-24-004541 | Dec 6, 2024 | — |
| 8-K | 8-K | 0000950170-24-127708 | Nov 18, 2024 | Nov 15, 2024 |
| 8-K | 8-K | 0000950170-24-124545 | Nov 12, 2024 | — |
| SC 13G/A | — | 0002012383-24-004032 | Nov 8, 2024 | — |
| SC 13G/A | SEC SCHEDULE 13G | 0000902219-24-000479 | Nov 8, 2024 | — |
| 8-K | 8-K | 0000950170-24-121437 | Nov 5, 2024 | — |
| 10-Q | 10-Q | 0000950170-24-121439 | Nov 5, 2024 | Sep 30, 2024 |
| 8-K | 8-K | 0000950170-24-120673 | Nov 4, 2024 | — |
| SC 13G/A | — | 0002012383-24-000892 | Oct 21, 2024 | — |
| 8-K | 8-K | 0000950170-24-089235 | Aug 1, 2024 | — |
| 10-Q | 10-Q | 0000950170-24-089241 | Aug 1, 2024 | Jun 30, 2024 |
| 4 | PRIMARY DOCUMENT | 0001562180-24-005118 | Jun 17, 2024 | Jun 14, 2024 |
| 3 | PRIMARY DOCUMENT | 0001562180-24-004086 | May 16, 2024 | May 15, 2024 |
| 4 | PRIMARY DOCUMENT | 0001562180-24-004087 | May 16, 2024 | May 15, 2024 |
| 8-K | 8-K | 0000950170-24-060462 | May 15, 2024 | May 14, 2024 |
| 8-K | 8-K | 0000950170-24-055052 | May 8, 2024 | — |
| 10-Q | 10-Q | 0000950170-24-055053 | May 8, 2024 | Mar 31, 2024 |
| ARS | ARS | 0000950170-24-040230 | Apr 2, 2024 | Dec 31, 2023 |
| DEF 14A | DEF 14A | 0000950170-24-040099 | Apr 2, 2024 | Mar 27, 2024 |
| DEFA14A | DEFA14A | 0000950170-24-040128 | Apr 2, 2024 | — |